To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

PHASE4WithdrawnINTERVENTIONAL

Timeline

Start Date

September 30, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Fabry Disease

Interventions

DRUG

agalsidase beta (GZ419828)

Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,

DRUG

agalsidase alfa

Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion